Orengedokuto and berberine improve indomethacin-induced small intestinal injury via adenosine

Journal of Gastroenterology

Volumn 44, Issue 5, 2009, Pages 380-389

  Watanabe Fukuda, Yoko ^a   Yamamoto, Masahiro ^a   Miura, Naoko ^a,b   Fukutake, Masato ^b   Ishige, Atsushi ^a   Yamaguchi, Rui ^c   Nagasaki, Masao ^c   Saito, Ayumu ^c   Imoto, Seiya ^c   Miyano, Satoru ^c   Takeda, Junzo ^a   Watanabe, Kenji ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TSUMURA AND CO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adenosine deaminase; Herbal medicine; Microarray; Nonsteroidal anti inflammatory drug; Small intestinal injury

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE DEAMINASE; BERBERINE; COPTIS RHIZOME EXTRACT; GARDENIA EXTRACT; HERBACEOUS AGENT; INDOMETACIN; ORENGEDOKUTO; PHELLODENDRON EXTRACT; PLANT EXTRACT; SCUTELLARIAE RADIX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BIOINFORMATICS; CONTROLLED STUDY; CORK TREE; DRUG EFFICACY; DRUG MECHANISM; ENTEROPATHY; ENZYME DEGRADATION; FEMALE; GENE EXPRESSION; GENE TECHNOLOGY; GENETIC ANALYSIS; IN SITU HYBRIDIZATION; INCIDENCE; LETHALITY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION;

ADENOSINE; ADENOSINE DEAMINASE; ALKALOIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BERBERINE; DRUGS, CHINESE HERBAL; FEMALE; GENE EXPRESSION PROFILING; INDOMETHACIN; INTESTINAL DISEASES; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; RECEPTOR, ADENOSINE A2A;

EID: 67349159840     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0005-2     Document Type: Article

References (30)

1. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133-41.
2. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-8.
3. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-9.
4. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-47.
5. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1989;34:407-11.
6. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: A prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008;43:270-6.
7. Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: A cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5:1040-5.
8. Miura N, Fukutake M, Yamamoto M, Ohtake N, Iizuka S, Imamura S, et al. An herbal medicine orengedokuto prevents indomethacin-induced enteropathy. Biol Pharm Bull. 2007;30:495-501.
9. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins. 1977;14:333-41.
10. Whittle BJ, Laszlo F, Evans SM, Moncada S. Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol. 1995;116:2286-90.
11. Yamaguchi R, Yamamoto M, Imoto S, Nagasaki M, Yoshida R, Tsuiji K, et al. Identification of activated transcription factors from microarray gene expression data of Kampo medicine-treated mice. Genome Inform. 2007;18:119-29.
12. Nagasaki M, Doi A, Matsuno H, Miyano S. Genomic Object Net: I. A platform for modelling and simulating biopathways. Appl Bioinformatics. 2003;2:181-4.
13. Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: New insights into an old problem. J Gastroenterol. 1997;32:127-33.
14. Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res. 1999;40:517-24.
15. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-5.
16. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, et al. Mitochondrial damage: A possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut. 1997;41:344-53.
17. Basivireddy J, Vasudevan A, Jacob M, Balasubramanian KA. Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes. Biochem Pharmacol. 2002;64:339-49.
18. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, et al. Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol. 1998;124:1385-94.
19. Antoon JS, Perry MA. Role of neutrophils and mast cells in acute indomethacin-induced small bowel injury in the rat. J Gastroenterol. 1997;32:747-57.
20. Miura S, Suematsu M, Tanaka S, Nagata H, Houzawa S, Suzuki M, et al. Microcirculatory disturbance in indomethacin-induced intestinal ulcer. Am J Physiol. 1991;261:G213-9.
21. Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T. Reduced conscious blood flow in the stomach during non-steroidal anti-inflammatory drugs administration assessed by flash echo imaging. Scand J Gastroenterol. 2007;42:1040-4.
22. Nishizawa T, Suzuki H, Masaoka T, Hibi T. Education and imaging. Gastrointestinal: Enhanced gastric mucosal blood flow in aspirin intoxication. J Gastroenterol Hepatol. 2007;22:2037.
23. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527-52.
24. Hasko G, Cronstein BN. Adenosine: An endogenous regulator of innate immunity. Trends Immunol. 2004;25:33-9.
25. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, et al. Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:566-74.
26. Kolachala VL, Bajaj R, Chalasani M, Sitaraman SV. Purinergic receptors in gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2008;294:G401-10.
27. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology. 2005;129:26-33.
28. Cavalcante IC, Castro MV, Barreto AR, Sullivan GW, Vale M, Almeida PR, et al. Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006;74:2606-12.
29. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G, et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther. 2007;322:435-42.
30. Pouliot M, Fiset ME, Masse M, Naccache PH, Borgeat P. Adenosine up-regulates cyclooxygenase-2 in human granulocytes: Impact on the balance of eicosanoid generation. J Immunol. 2002;169:5279-86.